2021
DOI: 10.1007/s12020-021-02869-w
|View full text |Cite
|
Sign up to set email alerts
|

Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 54 publications
0
4
0
Order By: Relevance
“…This demonstrates that low VDR levels in ECs promote the development of endocrine tumors (gastrointestinal carcinoid tumors) in the midgut, consistent with findings of previous studies. Case studies in patients with intestinal carcinoid tumors have shown that VitD deficiency is common [55][56][57]. An association between VDR polymorphisms and the risks and outcomes of several malignancies such as colon cancer has been reported [34,35].…”
Section: Discussionmentioning
confidence: 99%
“…This demonstrates that low VDR levels in ECs promote the development of endocrine tumors (gastrointestinal carcinoid tumors) in the midgut, consistent with findings of previous studies. Case studies in patients with intestinal carcinoid tumors have shown that VitD deficiency is common [55][56][57]. An association between VDR polymorphisms and the risks and outcomes of several malignancies such as colon cancer has been reported [34,35].…”
Section: Discussionmentioning
confidence: 99%
“…Particularly, phosphoremia levels were lower in NF1 patients, though within the normal range. The lower phosphoremia could be related to the lower vitamin D and higher PTH levels observed in NF1 patients [ 25 ]. However, the clinical meaning of this finding is unclear and has to be confirmed and explained in further studies.…”
Section: Discussionmentioning
confidence: 99%
“…Clinical assessment included sex, age, BMI for both patients and controls, and evaluation of the 7 main clinical features according to NIH criteria for NF1 patients. BMI was calculated by weight and height (weight (kg) divided by height squared (m 2 ), kg/m 2 ] following standard criteria [ 24 , 25 ]. According to WHO’s criteria, patients were classified by BMI as normal weight (BMI 18.5–24.9 kg/m 2 ), overweight (BMI 25.0–29.9 kg/m 2 ), and obese (BMI ≥ 30.0 kg/m 2 [ 24 ].…”
Section: Experimental Designmentioning
confidence: 99%
“…Clinical characteristics, including age, sex, anthropometric measurements (i.e., height and weight), symptoms at diagnosis, smoking habits, comorbidities, tumor size, imaging procedures, type of surgical resection, assessment of lymph nodes metastasis, pathological tumor stage, adjuvant treatment, as well as follow-up and patient outcome were collected from medical records. Body mass index (BMI) was evaluated from the anthropometric measurements and was classified according to the WHO criteria as normal weight (BMI 18.5–24.9 kg/m 2 ), overweight (BMI 25.0–29.9 kg/m 2 ), and obesity (BMI ≥ 30.0 kg/m 2 ), as previously reported [ 27 , 28 , 29 ]. Symptoms at diagnosis were considered tumor mass-related or hormonal-related.…”
Section: Methodsmentioning
confidence: 99%